A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phase 3B, Protocol P06384).

Trial Profile

A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phase 3B, Protocol P06384).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Asenapine (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Actavis; Forest Laboratories; Merck Sharp & Dohme
  • Most Recent Events

    • 26 Sep 2017 According to results published in the American Journal of Psychiatry, study protocol was amended with relapse rate assumptions updated to 34% for the placebo group (hazard ratio=0.45) and to 17% for the asenapine group.
    • 26 Sep 2017 Primary endpoint (Time to recurrence of any mood event during the Double-Blind Treatment Period) has been met, according to results published in the American Journal of Psychiatry.
    • 26 Sep 2017 Results published in the American Journal of Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top